Gross Profit: Revenues from operations less the associated costs.
Recursion Pharmaceuticals, Inc. (RXRX) had Gross Profit of $2.63M for the most recently reported fiscal quarter, ending 2024-03-31.
Income Statement Financials | |
$13.79M |
|
$-91.37M |
|
$11.17M |
|
Gross Profit |
$2.63M |
$110.13M |
|
$-96.34M |
|
$4.19M |
|
$-92.15M |
|
$-92.15M |
|
$-91.37M |
|
$-91.37M |
|
$-91.37M |
|
$-91.37M |
|
$-96.34M |
|
$-88.96M |
|
236.02M |
|
236.02M |
|
$-0.39 |
|
$-0.39 |
|
Balance Sheet Financials | |
$343.62M |
|
$86.72M |
|
$214.23M |
|
$557.85M |
|
$73.92M |
|
$1.07M |
|
$82.78M |
|
$156.70M |
|
$401.15M |
|
$316.02M |
|
$401.15M |
|
237.51M |
|
Cash Flow Statement Financials | |
$-102.30M |
|
$-6.65M |
|
$13.90M |
|
$401.43M |
|
$306.15M |
|
$-95.28M |
|
$16.13M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
4.65 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
19.05% |
|
-698.42% |
|
-698.42% |
|
-- |
|
-668.06% |
|
-662.41% |
|
$-108.95M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
5.31 |
|
16.96 |
|
-22.78% |
|
-28.91% |
|
-16.38% |
|
-22.72% |
|
$1.69 |
|
$-0.46 |
|
$-0.43 |